Nephropathic Cystinosis Treatment Market is Expected to Reach Revenues of Approximately $263 Million by 2027

TMR picture

Nephropathic Cystinosis Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2019-2027

ALBANY, NEW YORK, USA, Jan. 31, 2022 /EINPresswire.com/ — According to the report, the global nephropathic cystinosis treatment market was valued at approximately US$215 million in 2018. It is expected to grow at a CAGR of ~2% over the forecast period of 2019 to 2027. Nephropathic cystinosis is an inherited disease in which the body accumulates the amino acid cystine (a building block of protein) in cells. Excess cystine forms crystals that can accumulate and damage cells. These crystals can negatively affect many body systems, especially the kidneys and eyes. Treatment options for nephropathic cystinosis include systemic depletion therapy, symptomatic therapy, and kidney transplantation. Cysteamine is the only effective treatment used for cystine depletion and is available in immediate-release and delayed-release capsules. North America led the global nephropathic cystinosis treatment market in 2018 and is expected to continue to lead by the end of 2027 in terms of revenue.

Request a report brochure –
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=32210

Emergence of patient assistance and helping hand programs for nephropathic cystinosis patients is driving the nephropathic cystinosis treatment market

The increase in public and private funding initiatives for cystinosis research and treatment and the emergence of patient assistance and helping hand programs for patients with nephropathic cystinosis are some of the major factors responsible growth of the global nephropathic cystinosis treatment market. For example, Horizon Therapeutics plc ran the Horizon Patient Services program, which is a patient support program that helps patients manage cystinosis. Product approvals by regulatory bodies and modification of dosage form for better patient compliance are also fueling the growth of the global nephropathic cystinosis treatment market. Moreover, the increased awareness among the people through various programs of different organizations is expected to boost the growth of the global Nephropathic Cystinosis Treatment market.

High treatment demand for the treatment of nephropathic cystinosis

On the basis of treatment type, the global nephropathic cystinosis treatment market has been divided into therapy and kidney transplantation. The therapeutic segment dominated the global nephropathic cystinosis treatment market in 2018 and its share in the global market has been increasing. Better efficiency in curing the symptoms, delayed kidney transplantation and new therapeutic approaches developed lately are some of the major factors responsible for the dominance of the therapeutic segment. The therapy segment is further sub-segmented into systemic depletion therapy and symptomatic therapy. Systemic depletion therapy is a more popular therapy as it is the only effective treatment option for nephropathic cystinosis.

Demand for Analysis of Impact of COVID-19 on Nephropathic Cystinosis Treatment Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=32210

Specialty/retail pharmacies will be a promising sales channel

In terms of sales channel, the global nephropathic cystinosis treatment market has been segmented into hospitals, specialty/retail pharmacies, and others. The hospital segment led the global market in 2018, driven by increasing patient admissions to hospitals for kidney treatment and transplantation, assistance in treatment reimbursement, and well-structured supply chain management. ‘supply. The specialty/retail pharmacy segment is expected to be a highly lucrative segment and grow at a high CAGR during the forecast period. This can be attributed to the ease of access to symptomatic therapies and cysteamine in retail pharmacies and to patient assistance programs by specialty pharmacies.

North America will dominate the global market

On the basis of region, the global nephropathic cystinosis treatment market has been segmented into five major regions: North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America accounted for a significant share of the global nephropathic cystinosis treatment market in 2018, owing to comparatively higher patient population diagnosed with nephropathic cystinosis in the region, availability of FDA approved products US and research funding for new therapeutic approaches. For example, according to the Cystinosis Research Network (CRN), cystinosis affects approximately 2,000 people worldwide, including just over 600 of those diagnosed living in the United States. Europe follows North America in terms of market share in 2018, due to higher number of reported cystinosis cases, presence of large companies, increase in funding for cystinosis treatment and research, and increase in demand for treatment of nephropathic cystinosis in Europe.

Buy Nephropathic Cystinosis Treatment Market Report –
https://www.transparencymarketresearch.com/checkout.php?rep_id=32210

Competition landscape

Horizon Therapeutics plc., Mylan NV, Chiesi Farmaceutici SpA and Recordati Rare Diseases are some of the major players in the global nephropathic cystinosis treatment market. The global nephropathic cystinosis treatment market is fragmented in number of players with the entry of several players especially in symptomatic therapy. The major players in the global market are Horizon Therapeutics plc, Mylan NV, Chiesi Farmaceutici SpA, Recordati Rare Diseases, AVROBIO, Inc., Leadiant Biosciences, Inc., Eloxx Pharmaceuticals, and GlaxoSmithKline plc. New product launch with change in dosage form, merger and acquisition, and patient assistance programs provided by companies for financial and other supports are some of the major strategies adopted by large companies. in the nephropathic cystinosis treatment market.

More trending reports by Transparency Market Research

Urinary Catheters Market: Urinary catheters help in emptying the bladder before or after surgery. Thus, increasing number of surgeries globally is boosting the sales prospects in the urinary catheters market.

Pulmonary Cardiac Devices Market: Rising number of respiratory failure treatments, heart implants, and different surgical procedures are fueling the sales prospects in the global pulmonary cardiac devices market. Rise in different health issues such as lung diseases and cardiovascular disorders is propelling the demand for heart-lung machines.

Rohit Bhisey
gtr
+1 5186181030
write to us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Comments are closed.